The obesity treatment market is rapidly shifting from weekly to monthly administration. Major domestic companies, including ...

Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: ...

Samsung Bioepis will be given a full license right for the novel long-acting semaglutide asset, and an option to license another asset from G2GBIO.

Samsung Bioepis and Epis NexLab, subsidiaries of Samsung Epis Holdings, have signed a joint research and licensing agreement ...

CD Formulation is well-prepared to serve the industry by offering efficient and effective solutions for the mass fabrication of microspheres. SHIRLEY, NY, UNITED ...

Samsung Bioepis and Epis NexLab ink research collaboration and license pact with G2GBIO to develop novel assets including long-acting semaglutide: Incheon, Korea Tuesday, March 17 ...